Full-Time

QC Chemist

Technical Support

Posted on 5/20/2025

Gilead Sciences

Gilead Sciences

10,001+ employees

Develops and commercializes biopharmaceuticals for various diseases

No salary listed

Junior, Mid

Cork, Ireland

Category
IT Support
IT & Security
Required Skills
Data Analysis
Requirements
  • relevant experience in test methods for biologic and biopharmaceutical products
  • Strong knowledge and understanding of cGMP, quality control (QC), and regulatory requirements for GMP laboratories in pharmaceutical industry
  • Advanced knowledge of current Good Laboratory Practices (GLPs) and current Good Manufacturing Practices (GMPs)
  • Hands-on experience with equipment qualification and analytical techniques such as CE-SDS, CEX-HPLC, SE-HPLC, cIEF, Peptide mapping, UPLC/HPLC is essential
  • Knowledge of software such as Empower, SOLO VPE and LIMS
  • Critical thinking skills and ability to solve moderately complex problems and good judgement in making recommendations
  • Six sigma tools for root cause analysis
  • Lean tools for efficiency optimisations
  • Excellent interpersonal skills and ability to work effectively with people from a wide range of skill levels and experience
  • Ability to work independently and as part of a team with internal and external partners, self-motivation and adaptability
Responsibilities
  • Analytical support of Method Validation/Transfers for Biological & Solid Oral Dose Products as appropriate with specific emphasis on Biologic/Large molecule activity
  • Execution of process and cleaning validation studies in support of New Product Introductions
  • Provision of technical support to Operations for investigations and optimisation projects
  • Deliver new technologies and continuous improvement initiatives to meet business requirements
  • Lead QC TS investigations/troubleshooting and technical projects within the function
  • Identify new equipment for new product transfers
  • Demonstrates skills in data analysis (ex: CE-SDS. CEX HPLC, SE-HPLC, cIEF, Peptide Mapping, UPLC etc,) and ability to critically evaluate data quality
  • Reviews data and results of testing to ensure compliance to appropriate specifications and protocols
  • Writes and executes protocols and reports
  • Assists in the training of QC staff
  • Writes and revises methods, specifications, and SOP’s as needed
  • May develop methods for performing cleaning validations
  • Executes analysis efficiently, consistently, and with high quality and suggests improvements
  • Acts as a resource for other employees within the department
Desired Qualifications
  • relevant experience with BSc degree in Biopharmaceutical Science, Chemisty or equivalent
  • Bio-analytical testing experience is essential per the techniques already listed

Gilead Sciences is a biopharmaceutical company that develops and sells medicines for various serious health conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company focuses on extensive research and development to create new therapies, which are then approved by regulatory authorities before being marketed to healthcare providers and pharmacies. Gilead stands out from its competitors by investing heavily in R&D and forming strategic partnerships, such as with SAP Ariba, to improve its supply chain and product offerings. The company's goal is to enhance health equity and access to care globally, working with communities to ensure that its medicines reach those in need.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Simplify Jobs

Simplify's Take

What believers are saying

  • Gilead's U.S. investment creates significant economic value and job opportunities.
  • AI technologies could lead to faster drug development cycles for Gilead.
  • Top five ranking in Most JUST list enhances Gilead's reputation and stakeholder trust.

What critics are saying

  • $202 million settlement may damage Gilead's reputation and increase regulatory scrutiny.
  • Layoffs of 150 employees, including senior management, may disrupt operations and morale.
  • Rise of AI drug discovery companies poses a competitive threat to Gilead's R&D model.

What makes Gilead Sciences unique

  • Gilead's oncology navigation grant program enhances cancer care through innovative solutions.
  • $11 billion investment in U.S. manufacturing boosts operational capabilities and innovation pipeline.
  • AI-driven drug discovery enhances R&D efficiency and cost-effectiveness for Gilead.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Company News

PR Newswire
Jun 1st, 2025
The Academy Of Oncology Nurse Patient Navigators And Gilead Sciences Partner To Launch Oncology Navigation Grant Program

GAINESVILLE, Fla., June 1, 2025 /PRNewswire/ -- The Academy of Oncology Nurse & Patient Navigators (AONN+) is proud to announce the launch of a groundbreaking grant program in partnership with Gilead Sciences aimed at advancing the field of oncology navigation and enhancing patient outcomes within the healthcare setting. This initiative is designed to support the creation, enhancement, and expansion of innovative tools that optimize efficiency and elevate the critical role of oncology navigators.Following the AONN+ call for grant submissions in April, healthcare leaders across the country responded with creative applications, software solution ideas and healthcare system improvements. AONN+ looks to announce the recipients of the award, valued up to $500,000, in June with project work to begin in the July time frame. The AONN+ grant application process and implementation support for awardees also included help from Amplity, AONN+'s association management partner and strategic collaborator."Through this funding mechanism, AONN+ and Gilead are committed to addressing persistent challenges in cancer care by empowering navigators to play a pivotal role in improving patient access to navigation services, removing barriers to cancer care, and supporting treatment adherence," says Candice Roth, MSN, RN, CENP, Executive Director, AONN+. "Navigator utilization continues to present significant opportunities for optimizing patient outcomes, and this program seeks to provide impactful solutions that directly tie proposed tools to measurable improvements in patient care.""As part of Gilead's Community Cancer Collective, we are proud to partner with AONN+ on this exciting initiative in support of the oncology community," said Darren Tayama, M.D., Vice President, US Medical Affairs, Oncology. "Together, AONN+ and Gilead are advancing the future of cancer care through innovative solutions in oncology navigation."About the Academy of Oncology Nurse & Patient Navigators , Inc

Labiotech
May 27th, 2025
Interleukin Therapeutics: 9 Companies To Follow In 2025

Newsletter Signup - Under Article / In Page"*" indicates required fields Interleukins — a group of signaling proteins that help immune cells communicate — have long been recognized as powerful tools in modulating immune responses. Over the years, companies have explored interleukin as treatments for cancer, autoimmune conditions, and inflammatory diseases. But while some interleukin-based drugs have reached the market, many early attempts were held back by toxicity and a lack of precision.Today, that’s starting to change. Advances in protein engineering, mRNA technology, and cell-targeted delivery have opened up new ways to harness interleukins more safely and effectively. Big pharma is already active in this space, but a growing number of smaller biotech companies are helping to push the field forward.In this list, we take a look at some of the most interesting biotech companies and emerging players developing interleukin therapeutics. Ankyra Therapeutics Headquarters: Cambridge, MassachusettsFounded: 2019Recent News: Presented preliminary phase 1 clinical data for ANK-101 at the AACR Annual MeetingAnkyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of cytokine-based treatments. The company’s lead candidate, ANK-101 (tolododekin alfa), is an interleukin-12 (IL-12) cytokine anchored to aluminum hydroxide, designed for localized delivery to tumors.ANK-101 employs Ankyra’s proprietary Anchored Immunotherapy Platform, which involves fusing IL-12 with an alum-binding peptide, allowing the complex to bind to aluminum hydroxide (Alhydrogel)

Fierce Pharma
May 8th, 2025
Gilead tees up $11B in new US manufacturing, R&D investments

This time it's Gilead coming to the table with a fresh $11 billion in hand to spend across its manufacturing and research centers in the U.S.

Gilead Sciences
May 7th, 2025
Gilead U.S. Investment to Create $43 Billion in Value to U.S. Economy

Gilead to invest $32 billion in U.S. manufacturing and R&D through 2030 and create more than 3,000 direct and indirect jobs by 2028

Constantine Cannon
May 5th, 2025
Gilead Pays $202M to Settle False Claims Act Kickback Charges

On April 29, the Department of Justice (DOJ) announced that California-based pharmaceutical giant Gilead Sciences agreed to pay $202 million to settle charges of violating the False Claims Act and Anti-Kickback Statute.

INACTIVE